An Australian invention designed to decrease the likelihood of patients remembering parts of their surgery and improve their recovery from anaesthesia has just completed a further stage of clinical trials at Royal Melbourne Hospital. The positive results following the completion of this trial are a significant development for BioPharmica's investee Cortical Dynamics.
Cellestis Limited (ASX: CST) is pleased to announce it has been advised by the Korean Food and Drug Administration (KFDA) that QuantiFERON(R)-TB Gold In-Tube has received regulatory approval in the Republic of Korea (South Korea); allowing sale of the test in the Republic of Korea.
Phosphagenics Limited ("Phosphagenics") (ASX: POH)(AIM: PSG)(OTCQX: PPGNY) today announced positive results of its Phase 1 clinical trial that showed its delivery technology, TPM, delivered leading pain-relief drug oxycodone through the skin without causing any disruption or irritation.
Ventracor (ASX: VCR) today welcomed a major milestone in the growth of the worldwide industry for Left Ventricular Assist Devices (LVADs).
The Annual General Meeting of Ventracor Limited was held in Brisbane on 24 October and was well attended. We were very grateful and pleased to see the continuing interest and support by our shareholders. All resolutions put to the meeting were passed.
Ventracor (ASX: VCR) today announced 10 US hospitals have implanted at least one VentrAssist(tm) as part of its US clinical trials, and that more centres are trained and awaiting availability of patients.
Stirling Products Limited (ASX: STI) advises shareholders that studies recently conducted at the University of Western Australia have confirmed the superior biological potency of R-salbutamol over racemic salbutamol.
